ACTC - Advanced Cell Technology | Stock Discussion Forums

Sponsor

Biotech / Medical | ACTC - Advanced Cell Technology

Previous 10 | Next 10

From: Savant

3/15/2012 8:37:36 PM

of 92

View: Annual Data | Quarterly Data

All numbers in thousands

Dec 31, 2011 Sep 30, 2011 Jun 30, 2011 Mar 31, 2011

Period Ending
Total Revenue		66	133	154	154
Cost of Revenue		23	17	282	23

Gross Profit		43	116	(128)	131

	Operating Expenses
	Research Development	2,979	4,036	1,532	1,475
	Selling General and Administrative	2,831	2,976	1,952	3,198
	Non Recurring	-	-	-	-
	Others	-	-	-	-

	Total Operating Expenses	-	-	-	-


Operating Income or Loss		(5,767)	(6,896)	(3,612)	(4,836)

	Income from Continuing Operations
	Total Other Income/Expenses Net	(6,063)	(45,350)	(936)	1,881
	Earnings Before Interest And Taxes	(11,830)	(52,246)	(4,548)	(2,660)
	Interest Expense	281	275	272	682
	Income Before Tax	(12,112)	(52,521)	(4,820)	(3,342)
	Income Tax Expense	-	-	-	-
	Minority Interest	-	-	-	-

	Net Income From Continuing Ops	(12,112)	(52,521)	(4,820)	(3,342)

	Non-recurring Events
	Discontinued Operations	-	-	-	-
	Extraordinary Items	-	-	-	-
	Effect Of Accounting Changes	-	-	-	-
	Other Items	-	-	-	-


Net Income		(12,112)	(52,521)	(4,820)	(3,342)
Preferred Stock And Other Adjustments		-	-	-	-

Net Income Applicable To Common Shares		(12,112)	(52,521)	(4,820)	(3,342)

Recommend | Keep | Reply | Mark as Last Read

From: Savant	3/16/2012 10:49:26 PM
	of 92

Timing and Pace of Trials.... Feb 16 Timing and Pace of Our Clinical Trials Greetings, As you are undoubtedly aware, last July we initiated the first-ever clinical trials using a cell therapy derived from human embryonic stem cells (hESCs) to treat various forms of macular degeneration. The end goal for our clinical trials is to test whether or not the retinal pigment epithelial (RPE) cells we make from hESCs are capable of homing to sites of injury in the retina, replacing the native RPE cells that are lost to disease, and ultimately reestablishing the function of this layer of cells in protecting photoreceptors from cell death, i.e. slowing or halting progressive vision loss. One of our ongoing trials is for Stargardt’s Macular Dystrophy (SMD, aka Stargardt’s Disease) and the other is for Dry Age-Related Macular Degeneration (Dry AMD). Last month we also initiated a European clinical trial for Stargardt’s Disease. That same week, we also published some exciting – albeit very preliminary data – relating to the patients treated last July, in The Lancet. To date, we have treated one patient with Dry AMD (at UCLA), and a total of four patients with SMD (three at UCLA, and one at Moorfields Eye Hospital in London). The recent treatment of the two SMD patients at UCLA represents the entire first cohort of patients for this initial dose of cells in the SMD trial. We are pleased to have both trials underway and delighted with the results we have reported so far. Clearly, though, the question arises: why does the Stargardt’s Disease trial appear to be moving along at a faster pace than the Dry AMD trial? This has no doubt been of particular interest to our investors, upon whom the vast size of the potential market for Dry AMD is not lost; a projected market upwards of $25-30 Billion in the US and Europe alone. I intend to briefly address this issue here. No Two Trials Alike No two clinical trials are exactly alike or proceed at exactly the same pace. There are a few reasons why patient treatment in our Dry AMD trial has lagged behind our SMD trial a bit. It can be summed up pretty much as follows: luck, age and regulatory factors. Any large-scale, complex project with a number of moving parts and other variables, no matter how well planned and thought through, is on some level affected by a random interplay of factors beyond the control of its planners. Clinical trials are no exception to this, and simple luck always comes into play on some level. In the case of the Dry AMD trial, four of the initial patients that principal investigator Dr. Steven Schwartz of UCLA had identified as good candidates from which to select patients two and three wound up being screened out of eligibility in the final battery of tests. The patients all passed initial health screenings, complete reviews of their medical records and extensive optical analyses. Sadly, on the eve of the surgeries, the longer lead time screenings for cancer and viral infections yielded previously unidentified positive results. These patients had surely been excited to participate in the trial, and my heart goes out to each of them. They have suffered already with blindness from macular degeneration, and now have another tough set of circumstances to deal with in their lives. This is, unfortunately, not an overly uncommon occurrence in clinical trials, but clearly it is more likely to happen in a trial with a patient population that tends to be elderly, by definition. Dry AMD is, after all, age-related, and an older patient population will invariably have more complicating health factors that could affect final eligibility to participate in a clinical trial. The Food and Drug Administration’s (FDA) protocol for our surgeries, as you are also likely aware, involves a course of immune suppression before and for a period of time after the transplant, and a patient’s ability to tolerate this without other adverse effects is a critical factor in inclusion in the study. The extremely poor visual acuity requirements in the FDA protocol result in a decidedly elderly patient population (with patients typically being 77 years old or so at the youngest). When that factor is combined with the requirement of an intact Bruch’s Membrane, and the general health-related restrictions mentioned above, it makes for a more challenging patient screening process in the dry AMD trial relative to that for the SMD trial. That being said, I am pleased to inform you that we are currently in the advanced stages of screening several more clinical trial candidates and are very confident that we will soon be able to treat two additional Dry AMD patients, rounding out the first cohort in the AMD trial. Thank you, as always, for your interest and support. Gary Rabin Chairman and CEO Advanced Cell Technology, Inc.

Share	Recommend \| Keep \| Reply \| Mark as Last Read

From: Savant	4/7/2012 11:22:26 AM
	of 92

ACT Announces Approval of Bascom Palmer Eye Institute as Additional Site for Stem Cell Clinical Trial for dry Age-Related Macular Degeneration Ranked as Number One Eye Hospital Eight Years in a Row by U.S. News & World Report, Bascom Palmer Will Participate as Site for ACT’s Phase I/II Clinical Trial Using Human Embryonic Stem Cell-Derived RPE Cells for dry AMD MARLBOROUGH, Mass. — Apr. 4, 2012 – Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the Bascom Palmer Eye Institute in Miami, Fla., has received institutional review board (IRB) approval as a site for the company’s Phase I/II clinical trial for dry age-related macular degeneration (dry AMD), using human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells. “We could not be more pleased that the Bascom Palmer Eye Institute has been approved as an additional site for our clinical trial for dry AMD,” said Gary Rabin, ACT’s chairman and CEO. “The prestigious Bascom Palmer Eye Institute is ranked as the number one ophthalmology hospital in the country by U.S. News & World Report eight years running, and has a particularly strong reputation in the area of macular degeneration. We are very much looking forward to working with Dr. Philip Rosenfeld, a renowned retina specialist and professor of ophthalmology at the University of Miami’s Miller School of Medicine, and the rest of his team.” The Phase I/II trial is a prospective, open-label study designed to determine the safety and tolerability of the hESC-derived RPE cells following sub-retinal transplantation into patients with dry AMD. The trial will ultimately enroll 12 patients, with cohorts of three patients each in an ascending dosage format. Further information about patient eligibility for the dry AMD study is available at www.clinicaltrials.gov; ClinicalTrials.gov Identifier: NCT01344993. About dry AMD Degenerative diseases of the retina are among the most common causes of untreatable blindness in the world. Age-related macular degeneration (AMD) is the leading cause of blindness in people over age 60 in the United States, and the vast majority of cases of AMD are of the “dry” form, which is currently untreatable. About hESC-derived RPE Cells The retinal pigment epithelium (RPE) is a highly specialized tissue located between the choroids and the neural retina. RPE cells support, protect and provide nutrition for the light-sensitive photoreceptors. Human embryonic stem cells differentiate into any cell type, including RPE cells, and have a similar expression of RPE-specific genes compared to human RPE cells and demonstrate the full transition from the hESC state. About Advanced Cell Technology, Inc. Advanced Cell Technology, Inc., is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit www.advancedcell.com. About Bascom Palmer Bascom Palmer Eye Institute of the University of Miami Miller School of Medicine — part of UHealth — the University of Miami Health System, is ranked the best eye hospital in the nation, as published in U.S. News & World Report. Having earned an international reputation as one of the premier providers of eye care in the world, Bascom Palmer is also ranked #1 in patient care and residency training by Ophthalmology Times. As the largest ophthalmic care, research and educational facility in the southeastern United States, it treats more than 250,000 patients with nearly every ophthalmic condition each year and more than 12,000 surgeries are performed annually. To date, the Institute has trained more than 900 physicians, clinicians and researchers, many of whom now lead academic and clinical ophthalmology centers worldwide. With nearly 80 faculty members and 1,200 staff, the Institute demonstrates exceptional expertise in every ophthalmic subspecialty. Founded in 1962, Bascom Palmer has patient care facilities in Miami, Palm Beach Gardens, Naples, and Plantation, Florida. For additional information, contact the office of marketing and communications at (305) 326-6190, bpeicommunications@med.miami.edu , or visit www.bascompalmer.org. Forward-Looking Statements Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company’s periodic reports, including the report on Form 10-K for the year ended December 31, 2011. Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. There can be no assurance that the Company’s clinical trials will be successful. Contact: Investors: CEOcast, Inc., James Young, 212-732-4300 Press: ACT Corporate Communications, Bill Douglass, 646-450-3615 or: Russo Partners, Martina Schwarzkopf, Ph.D., 212-845-4292 Business Development: Advanced Cell Technology, Matthew Vincent, Ph.D., mvincent@advancedcell.com 508-756-1212 x324

Share	Recommend \| Keep \| Reply \| Mark as Last Read

From: Savant	5/2/2012 8:46:18 AM
	of 92

Advanced Cell Technology Announces Webcast of Corporate Presentation at Annual Shareholders' Meeting Today Webcast to Commence at 9:15 a.m. PDT After Formal Portion of Meeting has Concluded MARLBOROUGH, Mass., Apr 26, 2012 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, announced that it will webcast today's corporate presentation at 9:15 a.m. PDT, after the formal portion of its Annual Shareholders' Meeting has concluded. Prior to the webcast, proxy voting will be completed and the results announced to the shareholders in attendance. The meeting is open to shareholders of record as of March 1, 2012. After the corporate presentation, the Company will address questions from shareholders in attendance, as well as electronically via the webcast. The webcast will be available live and via replay at: *** us.meeting-stream.com The Presentation schedule is as follows: -- Corporate Overview- Gary Rabin, Chairman and CEO -- Pre-clinical Programs Summary- Robert Lanza, M.D., CSO -- RPE Clinical Program Update and FDA planning for Phase 2- Ed Mickunas, VP of Regulatory and Clinical Affairs -- Financial Overview- Kathy Singh, Controller -- Strategic and Corporate Opportunities- Matt Vincent, Ph.D., Director of Business Development About Advanced Cell Technology, Inc. Advanced Cell Technology, Inc., is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit advancedcell.com. ============================ ACT Announces Massachusetts Eye and Ear as Additional Site for Clinical Trial for Dry Age-Related Macular Degeneration Using Human Embryonic Stem Cell-Derived RPE Cells Institutional Review Board (IRB) Approval for Phase I/II Clinical Trial for Dry AMD from Primary Teaching Hospital for Harvard Medical School in Ophthalmology MARLBOROUGH, Mass., May 02, 2012 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that Massachusetts Eye and Ear ("Mass. Eye and Ear") has received institutional review board (IRB) approval to be a site for the company's Phase I/II clinical trial for dry age-related macular degeneration (dry AMD), using human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells. "We are delighted to announce that Mass. Eye and Ear will participate as a site for our clinical trial for dry AMD," said Gary Rabin, ACT's chairman and CEO. "Dr. Dean Eliott and his team are deeply committed to finding new treatments for preventing blindness, and we very much look forward to tapping into his expertise and insight into the progression of macular degenerative disorders. The primary teaching hospital for ophthalmology at Harvard Medical School, Mass. Eye and Ear is ranked as among the top ophthalmology hospitals in the country by U.S. News & World Report and has a reputation that is unrivaled." The Phase I/II trial is a prospective, open-label study designed to determine the safety and tolerability of the hESC-derived RPE cells following sub-retinal transplantation into patients with dry AMD. The trial will ultimately enroll 12 patients, with cohorts of three patients each in an ascending dosage format. "Dry AMD represents one of the largest unmet medical needs in ophthalmology," commented Dr. Dean Eliott, M.D. a full time retina surgeon, scientist and Associate Director of the Retina Service at Mass. Eye and Ear. "We appreciate the opportunity to get some first-hand experience with the protocol and be involved with the international team that has been assembled around the U.S. and European trials." Founded in 1824, the Massachusetts Eye and Ear Infirmary is an independent specialty hospital affiliated with Harvard Medical School. Further information about patient eligibility for the dry AMD study is available at clinicaltrials.gov; ClinicalTrials.gov Identifier: NCT01344993. About dry AMD Degenerative diseases of the retina are among the most common causes of untreatable blindness in the world. Age-related macular degeneration (AMD) is the leading cause of blindness in people over age 60 in the United States, and the vast majority of cases of AMD are of the "dry" form, which is currently untreatable. About hESC-derived RPE Cells The retinal pigment epithelium (RPE) is a highly specialized tissue located between the choroid and the neural retina. RPE cells support, protect and provide nutrition for the light-sensitive photoreceptors. Human embryonic stem cells differentiate into any cell type, including RPE cells, and have a similar expression of RPE-specific genes compared to human RPE cells and demonstrate the full transition from the hESC state. About Advanced Cell Technology, Inc. Advanced Cell Technology, Inc., is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit advancedcell.com. About Massachusetts Eye and Ear Located in Boston, Massachusetts, the Massachusetts Eye and Ear Infirmary is an independent specialty hospital founded in 1824. Mass. Eye and Ear has earned an international reputation for its successful treatment of the most difficult diseases and conditions of the eye, ear, nose, throat, head and neck, and for its outstanding contributions to medical research and education. Mass. Eye and Ear is the primary teaching hospital for Harvard Medical School in ophthalmology and otolaryngology, and trains more than 110 residents and fellows each year in various sub-specialties, including cornea, neuro-ophthalmology, retina, eye pathology, pediatrics, glaucoma, ocular oncology, immunology, head and neck surgery and oncology, pediatric otolaryngology, facial plastics, otology and oto-neurology. For more information, visit masseyeandear.org. SOURCE: Advanced Cell Technology, Inc. Investors: CEOcast, Inc. James Young, 212-732-4300 or Press: ACT Corporate Communications Bill Douglass, 646-450-3615 or Russo Partners Martina Schwarzkopf, Ph.D., 212-845-4292 or Business Development: Advanced Cell Technology Matthew Vincent, Ph.D., 508-756-1212 x324 mvincent@advancedcell.com

Share	Recommend \| Keep \| Reply \| Mark as Last Read

From: Savant	5/17/2012 7:09:24 PM
	of 92

Advanced Cell Technology Announces 2012 First Quarter Results MARLBOROUGH, Mass., May 08, 2012 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today first quarter financial results for the period ended March 31, 2012. The Company reported a loss from operations of $(5.4) million compared to a loss from operations of $(4.8) million in the 2011 first quarter. ACT reported a net loss of $(5.7) million or $(0.00) per share, compared to a loss in the same period in 2011 of $(3.3) million, or $(0.00) per share. Net cash used in operations for the 2011 first quarter was $4.8 million, compared to net cash used in operations of $3.4 million in the same period in 2011. The Company ended the 2012 first quarter with cash and cash equivalents of $10.8 million, compared to $13.1 million as of December 31, 2011. Highlights from the first quarter of 2012 included: -- IRB approval from Wills Eye Institute in Philadelphia, one of the nation's top ophthalmology centers, to treat macular degeneration. -- Initiated Europe's first human Embryonic Stem Cell transplant at Moorfields Eye Hospital -- Published first report of human Embryonic Stem Cell (hESC)-derived cells transplanted into patients to treat macular degeneration in leading medical journal, The Lancet. -- Dosed additional patients in the company's clinical trial treating Stargardt's Disease. -- Added Aberdeen Royal Infirmary in Scotland as site for Phase I/II Clinical Trial using hESC-derived RPE cells for macular degeneration. "We are very pleased with our progress in the clinic so far," said Chairman and CEO Gary Rabin. "We are encouraged by the results we have seen from the early patients treated in each of our indications, and look forward to completing the trials on schedule." Conference call and Webcast The Company will hold a conference call tomorrow at 9 a.m. eastern time to discuss the first quarter results and business outlook. Interested parties may access the call live by dialing (888) 264-3177 and using conference ID 72827188. This event will be streamed via webcast. The webcast will be available at us.meeting-stream.com A replay of the call will also be available via the same link. About Advanced Cell Technology, Inc. Advanced Cell Technology, Inc., is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit advancedcell.com. Forward-Looking Statements Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-K for the year ended December 31, 2011. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. There can be no assurance that the Company's clinical trials will be successful. SOURCE: Advanced Cell Technology, Inc. CEOcast, Inc. Investors: James Young, 212-732-4300 or Press: ACT Corporate Communications Bill Douglass, 646-450-3615 or Russo Partners Martina Schwarzkopf, Ph.D., 212-845-4292 or Business Development: ACT Matthew Vincent, Ph.D., 508-756-1212 x324 mvincent@advancedcell.com

Share	Recommend \| Keep \| Reply \| Mark as Last Read

From: Savant	6/15/2012 1:07:58 AM
	of 92

Advanced Cell Technology to Present at the 2012 Bio International Convention and the Clinical Outlooks for Regenerative Medicine Meeting MARLBOROUGH, Mass., Jun 14, 2012 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the company is presenting at two upcoming conferences: the 2012 Bio International Convention and Clinical Outlooks for Regenerative Medicine meeting, both in Boston, on Tuesday, June 19. The presentations will cover the company's three ongoing clinical trials using human embryonic stem cell-derived retinal pigment epithelial cells to treat macular degeneration, and other programs. Gary Rabin, chairman and CEO, will present at the 2012 Bio International Convention on Tuesday, June 19 at 8:15 a.m. EDT, at the Boston Convention & Exhibition Center. Matthew Vincent, Ph.D., director of business development, will present at the Clinical Outlooks for Regenerative Medicine meeting at 9:15 a.m. EDT on the same date, at the Starr Center, Schepens Eye Research Institute, at 185 Cambridge Street in Boston. Both presentation slide decks will be available on the conference presentations section of the ACT website. About Advanced Cell Technology, Inc. Advanced Cell Technology, Inc., is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit advancedcell.com. Forward-Looking Statements Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-K for the year ended December 31, 2011. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. There can be no assurance that the Company's clinical trials will be successful. SOURCE: Advanced Cell Technology, Inc. Investors: CEOcast, Inc. James Young, 212-732-4300 or Press: ACT Corporate Communications Bill Douglass, 646-450-3615 or Russo Partners Martina Schwarzkopf, Ph.D., 212-845-4292 or Business Development: ACT Matthew Vincent, Ph.D., 508-756-1212, ext. 324 mvincent@advancedcell.com

Share	Recommend \| Keep \| Reply \| Mark as Last Read \| Read Replies (1)

To: Savant who wrote (59)	6/15/2012 1:11:19 AM
From: Savant	of 92

May 18th.. Advanced Cell Technology to Present at World Stem Cells & Regenerative Medicine Congress in London Chairman and CEO Gary Rabin to Discuss Three Ongoing Clinical Trials Using Human Embryonic Stem Cell (hESC)-Derived Retinal Pigment Epithelial (RPE) Cells to Treat Macular Degeneration MARLBOROUGH, Mass., May 18, 2012 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that chairman and CEO Gary Rabin will be presenting at the World Stem Cells and Regenerative Medicine Conference, May 21-23, in London. Mr. Rabin's presentation, titled "Successes and ongoing advancements of human clinical trials for the treatment of AMD & Stargardt's Disease," will be given on Monday, May 21 at 5:05 p.m. BST (London time). Mr. Rabin will provide an update on ACT's three ongoing human clinical trials in the U.S. and E.U. for Dry Age-Related Macular Degeneration (Dry AMD) and Stargardt's Macular Dystrophy (SMD). ACT recently announced Data and Safety Monitoring Board (DSMB) approval to move forward with enrollment and treatment of additional patients with SMD in its U.S. SMD trial, and to treat the final two patients to round out the initial dosing arm in its European trial. All three of the company's ongoing clinical trials use human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells. About SMD, Dry AMD and Degenerative Diseases of the Retina Stargardt's Macular Dystrophy (SMD) is one of the most common forms of macular degeneration in the world. SMD causes progressive vision loss, usually starting in children between 10 to 20 years of age. Eventually, blindness results from photoreceptor loss associated with degeneration in the pigmented layer of the retina, called the retinal pigment epithelium or RPE cell layer. Degenerative diseases of the retina are among the most common causes of untreatable blindness in the world. As many as thirty million people in the United States and Europe suffer from macular degeneration, which represents a $25-30 billion worldwide market that has yet to be effectively addressed. Approximately 10% of people ages 66 to 74 will have symptoms of macular degeneration, the vast majority the "dry" form of AMD -- which is currently untreatable. The prevalence increases to 30% in patients 75 to 85 years of age.

Share	Recommend \| Keep \| Reply \| Mark as Last Read

From: Savant	7/10/2012 9:54:42 AM
	of 92

Shares of Advanced Cell Technology Inc. (OTC: ACTC), a biotechnology company focused on the development and commercialization of human embryonic, induced pluripotency, and adult stem cell technology in field of regenerative medicine, has risen sharply in trading today. Advanced Cell Technology shares are currently trading 9.83% higher at $0.0693 on above average volume of 8.62 million. Advanced Cell Technology shares are gaining momentum after the company announced that it secured approval to move forward with increased RPE dosage for patients in clinical trial for dry age-related macular degeneration (dry AMD). ACTC said that the Data and Safety Monitoring Board (DSMB), which is an independent group of medical experts closely monitoring the company’s three ongoing clinical trials, gave approval to the company to proceed with enrollment and treatment of additional patients in its clinical trial for dry AMD. With the DSMB authorization, Advanced Cell Technology will now move forward with patient screening and enrollment for the second cohort. As per the trial protocol, the second cohort will be injected with 100,000 retinal pigment epithelial (RPE) cells derived from hESCs, which is twice the dosage given to the first cohort. Dry AMD is one of the largest unmet ophthalmological needs in the world. According to Gary Rabin, Chairman and CEO of Advanced Cell, dry AMD represents a potential market of $25 billion in the U.S. and Europe alone. Rabin said that the DSMB approval to move to the higher dosage of cells in the clinical trial for dry AMD represents a major milestone for Advanced Cell’s clinical programs. Rabin said that ACTC’s RPE program is now advancing rapidly, as the company is now screening at multiple ophthalmological centers for the fourth surgery in both its dry AMD trial and its U.S. SMD trial.

Share	Recommend \| Keep \| Reply \| Mark as Last Read

Previous 10 | Next 10